WHO ICTRP trial
Subcutaneous Trastuzumab Deruxtecan Phase 1 Trial.
CTIS2024-516625-31-00 · EU Clinical Trials Information System · Recruiting
Key facts
| Trial ID | CTIS2024-516625-31-00 |
|---|---|
| Public title | Subcutaneous Trastuzumab Deruxtecan Phase 1 Trial. |
| Scientific title | - DS8201-801 |
| Primary sponsor | Daiichi Sankyo Inc. |
| Registry | EU Clinical Trials Information System |
| Recruitment status | Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): Yes Therapeutic exploratory (Phase II): No Therapeutic confirmatory - (Phase III): No Therapeutic use - (Phase IV): No |
| Countries | Korea, Republic of;Taiwan;Japan;United States;France;Spain |
| Conditions | Advanced Solid Tumor MedDRA version: 21.1Level: LLTClassification code: 10065252Term: Solid tumor Class: 10029104;Therapeutic area: Diseases [C] - Neoplasms [C04] |
| Registration date | Oct 7, 2025 |
| Target size | 76 |
| Secondary IDs | NCT07015697 |
| Registry page | euclinicaltrials.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: